This product consists of a laboratory-formulated peptide blend containing Fragment 176–191, CJC-1295 (No DAC, Modified GRF 1–29), and Ipamorelin. The blend is supplied exclusively for research use to support investigation of coordinated growth hormone axis signaling, adipocyte-specific metabolic pathways, and receptor-selective endocrine mechanisms in preclinical experimental systems.

Biochemical Characteristics

Fragment 176–191 is a peptide segment corresponding to amino acids 176 through 191 of the human growth hormone (hGH) sequence. This region has been shown in experimental models to exhibit biological activity distinct from the growth-promoting domains of full-length growth hormone.

Research Applications

In preclinical research, Fragment 176–191 is studied for its role in adipocyte lipid metabolism, energy partitioning, and regulation of lipolytic signaling pathways. Investigations focus on adipose tissue–specific responses independent of classical growth hormone receptor activation.

Mechanistic Context

Experimental data suggest that Fragment 176–191 modulates adipocyte metabolic activity through signaling pathways associated with lipid mobilization and mitochondrial fatty acid utilization. These effects are evaluated in cellular and animal models designed to isolate growth hormone–independent mechanisms.

Biochemical Characteristics

CJC-1295 (No DAC), also known as Modified GRF (1–29), is a synthetic analog of growth hormone–releasing hormone (GHRH). It incorporates amino acid substitutions that enhance resistance to enzymatic degradation while retaining high affinity for the GHRH receptor (GHRHR). The absence of DAC conjugation results in shorter signaling persistence suitable for studies of pulsatile endocrine activity.

Research Applications

This peptide is utilized in laboratory research to examine hypothalamic–pituitary signaling, growth hormone release kinetics, receptor responsiveness, and downstream insulin-like growth factor (IGF) pathway modulation in preclinical models.

Mechanistic Context

CJC-1295 (No DAC) activates GHRHR-mediated G_s-protein signaling, leading to increased intracellular cyclic AMP (cAMP) levels and protein kinase A (PKA) activation. These cascades regulate transcriptional processes associated with growth hormone synthesis and secretion in pituitary-derived tissues.

Biochemical Characteristics

Ipamorelin is a synthetic pentapeptide that functions as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a). Its molecular structure confers high receptor specificity with minimal interaction with non-target pituitary hormone pathways in comparative in-vitro assays.

Research Applications

Ipamorelin is employed in preclinical studies to evaluate ghrelin receptor–dependent signaling, intracellular calcium mobilization, phospholipase C activation, and selective modulation of growth hormone secretagogue pathways in animal and cellular models.

Mechanistic Context

Binding of ipamorelin to GHSR-1a activates calcium-dependent intracellular signaling cascades that complement GHRH receptor–mediated pathways. These mechanisms are studied to characterize receptor synergy and endocrine pulsatility in experimental systems.

The combined use of Fragment 176–191, CJC-1295 (No DAC), and Ipamorelin in experimental research enables investigation of parallel and complementary signaling pathways within the growth hormone regulatory axis. CJC-1295 and ipamorelin engage distinct pituitary receptors (GHRHR and GHSR-1a, respectively), while Fragment 176–191 provides a model for growth hormone–independent metabolic signaling in adipose tissue.

Preclinical studies involving these peptides have examined endocrine pulsatility, receptor selectivity, adipocyte metabolism, skeletal matrix markers, and feedback regulation within growth hormone–associated pathways. All findings referenced in the scientific literature are derived exclusively from cellular assays and animal models and are intended to advance mechanistic and biochemical understanding.

This peptide blend is supplied as a lyophilized formulation for laboratory research use. Analytical characterization typically includes high-performance liquid chromatography (HPLC) and mass spectrometry to confirm identity, purity, and composition prior to experimental application.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [10] under the referenced citations.

1. M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. [PubMed]
2. R. Ferrer-Lorente, C. Cabot, J.-A. Fernández-López, and M. Alemany, “Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats,” Life Sci., vol. 77, no. 16, pp. 2051–2058, Sep. 2005. [PubMed]
3. F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. [PubMed]
4. M. C. Van Hout and E. Hearne, “Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions,” Subst. Use Misuse, vol. 51, no. 1, pp. 73–84, Jan. 2016. [PubMed]
5. K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]
6. E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
7. J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]
8. M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]
9. M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]
10.  Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.